2025/10/15 by Holly Fernandez Lynch, Xinping Hu, Alison Bateman-House · 1 voice
Chemistry · Pharmacology, Toxicology and Pharmaceutics · Psychology · #Chemical synthesis and alkaloids #Forensic Toxicology and Drug Analysis #Psychedelics and Drug Studies
paper · doi:10.1017/jme.2025.10183
openalex publication_date 2025/10/15 · openalex created_date 2025/10/16 · openalex updated_date 2026/07/02
Psychedelic medicines hold the promise of therapeutic benefit for many suffering from serious unmet mental health needs, leading to substantial demand even before these drugs receive FDA approval based on demonstrated safety and effectiveness for particular conditions. Recognizing FDA approval as the ideal path for psychedelics intended for medical use and drawing on lessons from medical marijuana, we encourage policymakers to balance the need for evidence, the importance of patient safeguards, and the desire for speed. They should increase support for psychedelic research, reject approaches that could inhibit that research, explore improvements to FDA's existing pre-approval access pathway, and avoid politically motivated FDA approval of psychedelic medicines.